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Introduction
Synthetic cannabinoids (SCBs) are chemicals that produce 
several marijuana-like effects in humans. In recent years, 
they have become increasingly abused as they are cheap, 
easily available on the internet, and are not detected by 
routinely employed urine toxicology screening tests (1,2). 
One in nine high school seniors admitted using SCBs in 
2011, making it the 2nd most prevalent illicit drug after 
marijuana (3). SCBs are dissolved in a volatile solvent and 
mixed with an assortment of plant leaves, such as Indian 
Warrior, Lion’s Ear, Dog Rose and/or Marshmallow leaves, 
which are themselves purported to have psychotropic 
effects upon smoking (4). Uneven distribution of SCBs to 
the plant mixture can result in drug “hot spots”, making 
dosing unpredictable and difficult, increasing the risk of 
overdose (5). There are commercially available, quasi-legal, 
unregulated ‘‘herbal incense’’ under names such as K2, K3, 
Spice, Smoke and Dream, just to name a few (6). 
While usually labeled “not for human consumption” 
distributors and consumers understand that these 
products are to be used like marijuana primarily to attain a 
subjectively pleasant cannabimimetic psychotropic effects. 
This label has kept these products from being subjected 
to the Federal Analogue Act of 1986. This transfers all 
responsibility for the user’s safety from the manufacturers 
and distributors to the consumer, who is often unaware of 
the product’s potential danger (7). The most infamous of 
which are JWH- 018, JWH-073, JWH-200, CP-47, 497 
and cannabicyclohexanol (7). Reports of acute kidney injury 
(AKI) attributed to it are on the rise but the underlying 
pathophysiology is elusive (8). Previous reports of AKI have 
shown diffuse patchy tubular injury favoring an ischemia 
related injury (8). We are reporting the first case of a young 
adult who presented with AKI after the use of SCBs and 
found to have biopsy proven thrombotic microangiopathy 
(TMA) as the major pathological pattern of the organ 
injury.
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cannabinoids (SCBs) has increased. Little is known about the potential adverse effects of SCBs especially in 
regards to their nephrotoxicity. Case reports of acute kidney injury (AKI) from acute tubular injury secondary 
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unknown. We report the first case of biopsy proven thrombotic microangiopathy (TMA) associated with 
SCBs resulting in AKI. The patient suffered significant morbidity with loss of renal function eventually 
requiring renal replacement therapy.
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Case presentation
A 20-year-old man with no prior medical history presented 
to the emergency department after 2 episodes of generalized 
tonic-clonic seizures as witnessed by his mother. He 
complained of nausea and vomiting prior to the seizure. 
On arrival, he was conscious, then suffered from another 
3-minute seizure episode. Intravenous levetiracetam 
1,000 mg was given as initial treatment. Patient had no 
past history of seizures. His initial blood pressure was 
176/88 mmHg and heart rate was 104/minute. Physical 
examination was otherwise unremarkable. He underwent 
computed tomography of his head, which was negative for 
bleeding or any other pathology. 
Admission labs were consistent with anemia and AKI, 
with hemoglobin of 8.3 mg/dL, hematocrit of 27.4 mg/dL, 
and elevated serum creatinine of 3.2 mg/dL. He developed 
thrombocytopenia  (p late lets  trended down from 
162,000/mm3 on admission, to 147,000/mm3 on day 1 
and 124,000/mm3 on day 2. On day 4 his serum lactate 
dehydrogenase levels were elevated at 309 U/L increasing 
to 530 U/L on day 10. Schistocytes were noted on 
peripheral smear and serum haptoglobin level low, less than 
8 mg/dL, consistent with intravascular hemolysis. Initial 
urinalysis showed a specific gravity of 1.018, 3+ protein, 
5–10 red blood cells per high power field, and RBC casts 
on urine microscopy. Urine protein to creatinine ratio was 
5.06 on spot testing. A routine drug screen was positive 
for tetrahydrocannabinol. Serological investigation was 
negative for antinuclear antibody (ANA), anti-neutrophil 
cytoplasmic antibody (ANCA), anti-glomerular basement 
membrane (GBM) antibody, hepatitis screens, and HIV 
antibody screen. 
Renal ultrasound was unremarkable. Since the patient 
admitted to daily use of SCBs over the prior few weeks, 
a sample was sent to the University of California in San 
Francisco for toxicology analysis and showed the presence 
of CP 47, CP 497 and Hebrew University (HU) 320. Due 
to worsening renal function, a kidney biopsy was performed 
and revealed thrombotic macroangiopathic lesions affecting 
the glomeruli with acute tubular injury (Figure 1A-C). The 
ADAMTS-13 (a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13) levels, which are 
less than 10% in TTP, were within the normal range (67% 
activity) which ruled out TTP. A clinical diagnosis of drug-
induced thrombotic microangiopathy (DITMA) with the 
concern of an atypical hemolytic uremic syndrome (aHUS) 
was suspected. Shiga toxin producing Escherichia coli 
testing was not performed, as the patient did not have any 
diarrhea. The patient initially received plasmapheresis with 
no response and was eventually started on hemodialysis. 
The concern for aHUS possibly triggered by SCBs was 
raised and treatment with complement blockade was offered 
but the patient initially refused. 
An endomyocardial  biopsy was performed due 
to significant decline of the left ventricular ejection 
fraction to assess for possible need of simultaneous heart 
transplantation (Figure 1D). Pathology was consistent 
with TMA affecting small vessels. The patient eventually 
underwent renal transplantation with eculizumab added to 
his anti-rejection regimen. He did not consent to genetic 
testing and the post-transplant serum creatinine level at 
6 months was 1.4 mg/dL and the platelets count returned to 
normal range, at 223,000/mm3.
Discussion
Thrombotic microangiopathies are life-threatening 
ailments secondary to small vessel platelet microthrombi. 
Clinical features include microangiopathic hemolytic 
anemia (MAHA) with thrombocytopenia and AKI, 
sometimes associated with neurologic abnormalities and 
cardiac ischemia. The underlying pathophysiology of TMA 
is endothelial damage of multiple etiologies. Etiology of 
primary  TMA include hereditary or acquired conditions, 
such as thrombotic thrombocytopenic purpura (TTP), 
shiga-toxin-producing Escherichia coli (STEC) hemolytic 
uremic syndrome (HUS), DITMA, hereditary or acquired 
complement-mediated TMA and rare hereditary disorders 
of vitamin B12 metabolism.
DITMA is important to diagnose as it is a preventable 
cause of TMA, generally managed first by withdrawing 
the suspected drug. The diagnosis of DITMA is made 
clinically with findings of MAHA and TMA associated 
with concurrent drug exposure. However, management of 
a patient with suspected DITMA may be challenging as 
DITMA and other primary thrombotic microangiopathies 
including TTP and complement-mediated TMA, have 
a similar clinical presentation but require different 
management modalities. A detailed clinical history is the 
key to making the correct diagnosis. 
Recently published systematic review included 78 drugs 
known to cause TMA (9). We propose adding SCBs to this 
list. Individual agents identified in the reported case include 
CP 47, CP 497, and HU 320. Using the “Criteria for 
Assessing Reports of Drug-Induced Thrombocytopenia and 
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Levels of Evidence for a Causal Relation between the Drug 
and Thrombocytopenia” in our patient, a probable level of 
causality can be ascertained as described (10). These include 
that the suspected drug was taken before thrombocytopenia 
occurred and recovery from thrombocytopenia was 
complete and sustained after the drug was discontinued. 
Moreover, the suspected drug should be the only drug 
taken before the onset of thrombocytopenia, or other drugs 
were continued or reintroduced with a sustained normal 
platelet count. Additionally, to the extent possible with 
secondary documentation, all other potential causes of 
thrombocytopenia were reasonably excluded (10). This is 
further presented in Table 1.
The exact mechanism of drug induced TMA remains 
elusive but some reports suggest an idiosyncratic, acute 
immunologic reaction whereas others suggest a direct toxic 
effect, which may be either acute dose-related toxicity or 
chronic dose and duration-dependent toxicity (11). Some 
patients had severe kidney injury and were described 
as having HUS; others had minimal kidney injury. It is 
Figure 1 Renal and cardiac biopsy of patient. (A) Representative H&E stained image of a glomerulus and an adjacent arteriole showing 
thrombotic microangiopathy (3 prong arrow). Glomerulus displays focal mesangial expansion with increase in reticulated matrix material 
associated with partial endocapillary obliteration and focal double contouring of the capillary walls (arrow) (×100); (B) a trichrome stained 
section reveals marked tubular injury possibly secondary to marked vascular and microvascular thrombotic microangiopathy (×50); (C) 
representative electron microscopic image of a glomerular capillary showing mesangial expansion with increase in granulated mesangial 
matrix associated with circumferential mesangial interposition and double contouring of capillary walls (arrow) (×5,000); (D) representative 
cardiac biopsy showing marked edematous thickening and obliteration of 2 inter myocytic arterioles (thick arrows). A normally patent 
arteriole is also present (thin arrow mid bottom area).
A
C
B
D
Table 1 Pathogenesis of synthetic cannabinoid induced TMA
Mechanism Pros Cons
Complement 
dysfunction
Low suspicion for TTP (ADAMTS 
67%); low suspicion for HUS (no 
diarrhea or GI symptoms)
No genetic 
testing 
available
Drug induced 
TMA
Low suspicion for TTP (ADAMTS 
67%); low suspicion for HUS (no 
diarrhea or GI symptoms)
Definite criteria 
not met
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possible that patients with severe HUS presentation may 
have an underlying complement dysregulation. 
Inherited and acquired complement alternative pathway 
dysregulation, is related to various renal diseases by 
defective complement control, leading to the deposition of 
activated products, known as C3 glomerulopathies. Current 
modalities of treatment available for complement regulation 
include blockade with the anti-C5 monoclonal antibody 
eculizumab or by plasma substitution with success seen in 
several cases (12).
The agents included in SCBs may provide the second 
hit by unmasking the abnormality resulting in endothelial 
damage.  Our patient failed to respond with plasmapheresis 
which makes it more likely that TMA was caused either by 
the direct toxic effect of these substances or by unmasking 
an underlying complement dysregulation. 
There are various reports of kidney injury secondary 
to SCB related with acute tubular injury or allergic 
interstitial nephritis as the predominant clinical diagnosis, 
with no reported cases of biopsy proven TMA. There 
were four cases reported in which  AKI was associated 
with synthetic cannabinoids with acute tubular injury as 
predominant pathology in renal biopsy (13). The Center for 
Disease Control and Prevention reported 16 cases of SCB 
induced AKI in multiple states with acute tubular injury 
demonstrated on 6 renal biopsies out of 8 performed, and 
acute interstitial nephritis found in 3 of 8 biopsies (14). 
We are reporting for the first time SCB induced acute 
injury associated with biopsy proven TMA/vasculopathy in 
both kidney and heart.  Arterioles and arteries of all sizes up 
to arcuate size were affected. In view of the marked vascular 
involvement including those of larger size, it was concluded 
that acute tubular injury was most likely secondary to severe 
vasculopathy.  TMA may be more prevalent in SCBs but 
perhaps remain underreported due to the lack of renal 
biopsy in the majority of such cases. 
Cannabinoid 1 and cannabinoid 2 receptors are present 
in almost all cell types in the kidney and play an important 
role in regulating normal renal physiology via the 
endocannabinoid system (15). Changes in these receptors 
are seen in pathological states like diabetic nephropathy, 
which causes  the cannabinoid 2 receptor downregulation. 
Cannabinoid 1 receptor upregulation has been documented 
in IgA nephropathy, in acute interstitial fibrosis, and in 
mesangial fibrosis (16). One may postulate a cannabinoid 
receptor mediated injury to endothelial cells and/or 
podocytes, serves as an initial insult interfering with vascular 
endothelial growth factor receptor, leading to thrombosis 
and TMA.
Conclusions
The reported case represents the first biopsy-proven TMA 
secondary to SCB, not previously reported in English 
literature.  We recommend adding SCB to the list of drugs 
associated with DITMAs. The implication that SCBs has 
deleterious effects, including DITMA necessitates further 
regulation on the manufacturing and selling of SCBs. 
Clinicians should be aware of these effects of SCBs as the 
drug has become more popular and these have not been 
reported with marijuana use. Further reporting and research 
of the SCBs and marijuana effects could better characterize 
SCBs association with renal injury. 
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